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Abstract Hepatitis B virus surface mutants are of enormous
importance because they are capable of escaping detection by
serology and can infect both vaccinated and unvaccinated pop-
ulations, thus putting the whole population at risk. This study
aimed to detect and characterise hepatitis B-escaped mutants
among blood donors and vaccinees. One thousand serum sam-
ples were collected for this study from blood donors and vac-
cinees. Hepatitis B surface antigen, antibodies and core anti-
bodies were tested using a commercial enzyme-linked immu-
nosorbent assay (ELISA) kit. DNA detection was performed
via nested polymerase chain reaction (PCR), and the S gene
was sequenced and analysed using bioinformatics. Of the 1,
000 samples that were screened, 5.5 % (55/1,000) were found
to be HBsAg-negative and anti-HBc- and HBV DNA-positive.
All 55 isolates were found to belong to genotype B. Several
mutations were found across all the sequences from synony-
mous and non-synonymous mutations, with the most nucleo-
tide mutations occurring at position 342, where adenine was
replaced by guanine, and cytosine at position 46 was replaced
by adenine in 96.4 % and 98 % of the isolates, respectively.
Mutation at position 16 of the amino acid sequence was found
to be common to all the Malaysian isolates, with 85.7 % of the
mutations occurring outside the major hydrophilic region. This
study revealed a prevalence of 5.5 % for hepatitis B-escaped
mutations among blood donors and vaccinated undergraduates,
with the most common mutation being found at position 16,
where glutamine was substituted with lysine.
Introduction
Hepatitis B virus (HBV) is the most common chronic viral
infection worldwide, affecting about 2 billion people globally,
with 378 million chronic carriers [1]. The HBV genome en-
codes four genes, called C, X, P and S. The C gene codes for a
core protein known as the hepatitis B core antigen (HBcAg),
while the X gene encodes the X protein, which is the protein
that circulates in the blood of infected individuals when there
is active viral replication [2]. HBsAg has a long open-reading
frame (ORF), which has three in-frame ‘start’ codons (ATG)
that split the gene into three sections: PreS1, PreS2 and S. As a
result of the numerous start codons, different-sized polypep-
tides are produced, known as the large (PreS1 + PreS2 + S),
medium (PreS2 + S) or small (S) polypeptides [3].
The hepatitis B surface antigen is a spherical particle that
measures 22 mm in diameter. Its determinant is a double-loop
structure, which projects from the surface of the virion and
forms the key neutralising epitope [4]. This determines the
surface antigen known as the ‘a’ determinant gene, and is
S. A. Hudu :M. I. Saeed :A. S. Alshrari :M. T. Niazlin :
Z. Sekawi (*)
Department of Medical Microbiology and Parasitology, Faculty of
Medicine and Health Sciences, Universiti Putra Malaysia, 43400





Department of Medical Microbiology and Parasitology, Faculty of
Basic Medical Sciences, College of Health Sciences, Usmanu
Danfodiyo University Sokoto, 840232 Sokoto, Sokoto State, Nigeria
Y. A. Malik
Department of Clinical Science, Faculty of Medicine and Health
Sciences, Universiti Tunku Abdul Rahman, Kuala Lumpur, Malaysia
N. S. Harmal
Department of Medical Microbiology, Faculty of Medicine and
Health Sciences, Sana’a University, Sana’a, Yemen
R. Hassan
National Blood Centre Malaysia, Jalan Tun Razak, Kuala
Lumpur 504000, Malaysia
Eur J Clin Microbiol Infect Dis (2015) 34:1349–1359
DOI 10.1007/s10096-015-2358-1
the main target for the vaccine, including antibodies. Howev-
er, mutation in the surface protein as a result of amino acid
deletions or substitutions, particularly in the region of amino
acids 137–147, permits hepatitis B virus replication in vacci-
nated subjects. This is because antibodies induced by the cur-
rent vaccine may not recognise changes in the surface antigen
as a result of transformation (mutation). HBV surface mutants
are of enormous importance because they are capable of in-
fecting both vaccinated and unvaccinated individuals, thus
putting the whole population at risk. Clinically important hep-
atitis B mutants have been reported in all genotypes [5], indi-
cating a wide spread across the various genotypes. Therefore,
understanding the prevalence of such mutations would be
useful for the design of a diagnostic assay and in the preven-
tion and treatment of HBV. However, extensive molecular
characterisation of occult hepatitis B strains in Southeast Asia
has not been performed. This study provides new information
regarding the phylogenetic analysis of vaccine-escaped hepa-
titis B strains obtained from blood donors and vaccinated un-
dergraduate volunteers in Malaysia.
Patients and methods
Sample collection
A total of 1,000 serum samples were collected for this study:
500 samples from blood donors at the National Blood Centre
Malaysia in Kuala Lumpur and 500 samples from volunteer
undergraduate students of the Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia (Table 1).
Serological assay
The National Blood Centre Malaysia performed HBsAg test-
ing using an ABBOTT PRISM instrument (Abbott Laborato-
ries, Abbott Park, IL, USA). Each of the samples was re-tested
for HBsAg in the laboratory of Medical and Molecular Virol-
ogy, Faculty of Medicine and Health Sciences, Universiti
Putra Malaysia. Anti-HBs, HBsAg and anti-HBc were tested
using a commercial enzyme-linked immunosorbent assay
(ELISA) kit (DRG International, Inc., New York, USA), ac-
cording to the manufacturer’s instructions. Twenty randomly
selected samples were sent to a commercial laboratory to ver-
ify the result of our ELISA. The sensitivity for the serological
assays was 10 IU/L optical density (OD≥0.105), 0.5 ng/mL
(OD≥0.105) and 2 ng/mL (OD≤0.600).. Sera with repeatedly
positive results were considered positive and those with re-
peatedly negative results were considered negative for each of
the serological markers.
HBV DNA isolation and detection from serum
HBV DNA was extracted from 200 μl of serum using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. Briefly, 20 μl of
protease was placed into a 1.5-μl tube, and 200 μl of the serum
andALbuffer was added to each tube before being vortexed and
incubated at 56 °C for 10 min. Then, 200 μl of ethanol was
added to enhance DNA precipitation. To eliminate impurities,
the trappedDNAwaswashed in two steps using AW1 andAW2
buffer as the first and second steps, respectively. The DNAwas
eluted with 50 μl of elution buffer and stored at −20 °C.
Two sets of primers were designed to amplify the S gene in
a nested polymerase chain reaction (PCR). The first round
targeted a 916-bp segment of the envelope gene and the sec-
ond round of PCRwas performed using the internal primers to
amplify 656 bp of the S gene (Table 2). Samples were handled
in aseptic conditions and all PCR reactions were carried out in
duplicate. In the first round was performed using 20 μl of
reaction mixture containing 0.5 μl DNA sample, 10 μl
Maxime PCR PreMix Kit (i-pfu) (iNtRON Biotechnology
Inc., Korea), 0.5 μl of each forward and reverse primer, and
8.5 μl nuclease-free water. The second round was performed
in a 50-μl reaction mixture containing 1 μl DNA sample,
25 μl Maxime PCR PreMix Kit (i-pfu) (iNtRON Biotechnol-
ogy Inc., Korea), 1.25 μl of each forward and reverse primer,
and 21.5 μl nuclease-free water. The PCR conditions com-
prised an initial denaturation step of 5 min at 94 °C, 30 cycles
of 94 °C for 5 min, 94 °C for 30 s, 63.8 °C for 30 s and 72 °C
for 60 s, and a final extension at 72 °C for 8 min; both reac-
tions were performed under the same conditions. The products
of amplification were recovered from a 1.5 % (w/v) agarose
gel using a DNA purification kit (Invitrogen Corporation, San
Diego, CA, USA), according to the manufacturer ’s
instructions.
Table 1 Distribution of study
populations and their
characteristics
Study cohort No. of samples HBsAg Anti-HBc PCR
Positive Negative Positive Negative
Blood donors 500 Negative 35 465 35 465
Undergraduate students 500 Negative 20 480 20 480
Total 1,000 1,000 55 945 55 945
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Sequencing and genotyping
The purified DNA of 55 sera from both blood donors and
vaccinated undergraduates was re-amplified using nested
PCR as described above, and the products were commercially
sequenced (First BASELaboratories, Selangor,Malaysia). All
sequences were submitted to the NCBIGenBank (http://www.
ncbi.nlm.nih.gov/genbank) under accession numbers
KC953665–KC953699 and KF011208–KF011227 for blood
donors and vaccinated undergraduates, respectively (Table 3).
The sequences were assembled using BioEdit v7.2.0, after
which they were manually edited to remove gaps or ambigu-
ously aligned sites. All sequences were aligned to reference
sequences from GenBank using ClustalW via Molecular Evo-
lutionary Genetics Analysis version 5 (MEGA 5) software [6].
Phylogenetic analysis was carried out using the maximum
likelihood (ML) method. Reference sequences were selected
from the GenBank database. For genotyping, our sequences
were aligned with S gene sequences from established HBV
genotypes A–I from the NCBI GenBank. The accession num-
bers are as follows: genotype A (AY161138, AJ309371), B
(AB0738554, AB073830), C (AF223960, X75656), D
(AY161159, AB090270), E (X75657, AB074845), F
(AF223963, AB036908), G (AF405706, M74499), H
(AY090457, AY090460) and I (FJ023667, AF241407). Evo-
lutionary history was inferred using the MLmethod, selecting
topology with a superior log likelihood rate. A distinct gamma
distribution was used to model evolutionary rate differences
among sites (+G, parameter = 0.7185). Genotypes were deter-
mined based on the genetic distance and clustering of the
DNA sequences [7].
Results
Of the 1,000 samples that were screened, 5.5 % (55/1,000)
were found to be HBsAg-negative and anti-HBc-positive, all
of which were found to be positive for HBV DNA by nested
PCR. Additionally, 84.8 % (848/1,000) of the samples were
anti-HBs-positive. The results of the nested PCR showed the
Table 2 Oligonucleotide primers used to amplify the hepatitis B S gene






HBsAg forward ACTGTCTCTGCCATATCGTCA 916
HBsAg reverse AACCCCAAAAGACCCACAA
Inner primer
HBsAg forward ACATGGAGAACATCGCATCAG 656
HBsAg reverse AATTGGTAACAGCGGTATAAAGG
Table 3 List of sequences submitted to the NCBI GenBank along with
their accession numbers




1 UPMD17 B 1-599 KC953665 Malaysia
2 UPMD47 B 1-598 KC953666 Malaysia
3 UPMD76 B 1-597 KC953667 Malaysia
4 UPMD79 B 1-598 KC953668 Malaysia
5 UPMD95 B 1-596 KC953669 Malaysia
6 UPMD110 B 1-592 KC953670 Malaysia
7 UPMD111 B 1-600 KC953671 Malaysia
8 UPMD124 B 1-594 KC953672 Malaysia
9 UPMD133 B 1-599 KC953673 Malaysia
10 UPMD138 B 1-582 KC953674 Malaysia
11 UPMD141 B 1-597 KC953675 Malaysia
12 UPMD161 B 1-594 KC953676 Malaysia
13 UPMD165 B 1-593 KC953677 Malaysia
14 UPMD16 B 1-599 KC953678 Malaysia
15 UPMD172 B 1-594 KC953679 Malaysia
16 UPMD197 B 1-575 KC953680 Malaysia
17 UPMD228 B 1-598 KC953681 Malaysia
18 UPMD265 B 1-593 KC953682 Malaysia
19 UPMD288 B 1-596 KC953683 Malaysia
20 UPMD290 B 1-595 KC953684 Malaysia
21 UPMD329 B 1-597 KC953685 Malaysia
22 UPMD348 B 1-596 KC953686 Malaysia
23 UPMD349 B 1-595 KC953687 Malaysia
24 UPMD351 B 1-593 KC953688 Malaysia
25 UPMD368 B 1-598 KC953689 Malaysia
26 UPMD375 B 1-593 KC953690 Malaysia
27 UPMD403 B 1-593 KC953691 Malaysia
28 UPMD459 B 1-596 KC953692 Malaysia
29 UPMD469 B 1-595 KC953693 Malaysia
30 UPMD518 B 1-597 KC953694 Malaysia
31 UPMD522 B 1-593 KC953695 Malaysia
32 UPMD525 B 1-593 KC953696 Malaysia
33 UPMD567 B 1-596 KC953697 Malaysia
34 UPMD301 B 1-604 KC953698 Malaysia
35 UPMD170 B 1-583 KC953699 Malaysia
36 UPMS45 B 1-622 KF011208 Malaysia
37 UPMS139 B 1-621 KF011209 Malaysia
38 UPMS140 B 1-622 KF011210 Malaysia
39 UPMS141 B 1-624 KF011211 Malaysia
40 UPMS148 B 1-621 KF011212 Malaysia
41 UPMS176 B 1-626 KF011213 Malaysia
42 UPMS181 B 1-627 KF011214 Malaysia
43 UPMS186 B 1-611 KF011215 Malaysia
44 UPMS189 B 1-611 KF011216 Malaysia
45 UPMS194 B 1-613 KF011217 Malaysia
46 UPMS318 B 1-621 KF011218 Malaysia
47 UPMS339 B 1-614 KF011219 Malaysia
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presence of a 656-bp band that was specific for the hepatitis B
S gene fragment, indicating a positive result (Fig 1). Of the
5.5 % (55/1,000) of the samples that were positive, 87.3 %
(48/55) were also hepatitis B surface antibody-positive, sug-
gesting immunity as a result of previous infection [8], while
12.7 % (7/55) were anti-HBs-negative. The latter group is
referred to as isolated anti-core, as has been previously de-
scribed [9]. However, none of these samples were hepatitis
B surface antigen-positive.
Multiple sequence alignment of Malaysia vaccine-escaped
hepatitis B strains revealed a sequence homology of 99 % and
a sequence identity that ranged from 83 to 100 %, and
pairwise distances ranging from 0.000 to 0.177, with an over-
all mean distance of 0.029. All of our isolates belonged to
genotype B, with some aberrant sequences showing a distant
relationship (Figs. 2 and 3). The majority of the Malaysian
isolates from blood donors fell into the first cluster (blue),
and were similar to the Panama isolate B2 and other isolates
from Japan, China and Taiwan. Two of our isolates fell within
the second cluster (red), together with isolates from Canada,
the Philippines and Indonesia. In the third cluster (green),
isolate UPMD197 showed a distant relationship with other
isolates, but was similar to isolate KC315324 from Thailand.
Malaysian isolates from vaccines are phylogenetically related
to other isolates from China, Taiwan and Japan, except for
isolates UPMS340, UPMS139, UPMS186, UPMS343 and
Table 3 (continued)




48 UPMS340 B 1-605 KF011220 Malaysia
49 UPMS343 B 1-605 KF011221 Malaysia
50 UPMS379 B 1-625 KF011222 Malaysia
51 UPMS388 B 1-611 KF011223 Malaysia
52 UPMS389 B 1-622 KF011224 Malaysia
53 UPMS402 B 1-621 KF011225 Malaysia
54 UPMS256 B 1-625 KF011226 Malaysia
55 UPMS354 B 1-610 KF011227 Malaysia
Fig. 1 Panel A shows the first-round polymerase chain reaction (PCR)
gel; panel B shows the second-round PCR gel from the sample of
students; panel C shows the controls and blank used in the experiment;
panel D shows the second-round PCR from blood donors. A 656-bp
DNA product was amplified using primers specific for the hepatitis B S
gene. All lanes show a PCR product of the expected size (B, C and D),
except lane A, which showed no band in the first round PCR. LD: 100-bp
molecular weight marker; PC: positive control;NTC: no-template control
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UPMS388, which were distantly related and belong to a dif-
ferent clade and sub-clades (Fig. 4). The most commonly oc-
curring nucleotide mutations were the replacement of adenine
at position 342 by guanine (A342G) and cytosine at position
46 by adenine (C46A); these were present in 96.4 % (53/55)
and 98 % (54/55) of the isolates, respectively.
Aligned deduced amino acid sequence showed correspond-
ing mutations at various points of the amino acid sequences of
the surface protein, including substitutions to deletions. The
mutation at amino acid 16 is common to all of the Malaysian
isolates, resulting in the substitution of glutamine (Q) with
lysine (K) in 53 of the isolates, while the remaining two iso-
lates contained an arginine residue or a stop codon. A total of
105 amino acid mutations were found in all 55 Malaysian
isolates; 85.7 % (90/105) were outside the major hydrophilic
region (MHR) and 14.3 % (15/105) were within the MHR, of
which 40 % (6/150) were within the a determinant region
(Table 4). The location of amino acid mutations within the
MHR (100–160 aa) and the a determinant region (124–147
aa) are shown in Fig. 5.
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Fig. 2 Molecular phylogeny of




genotypes (A to H) from the
NCBI GenBank. The blue
triangles indicate aberrant strains.
The evolutionary relationship was
inferred using the maximum
likelihood (ML) method based on
the Kimura model. Malaysian
isolates are indicated by HBV
UPM D followed by isolate
number and all belong to
genotype B, with the exception of
the aberrant strains
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Fig. 3 Phylogeny of the S gene
of 35 Malaysian isolates from
blood donors and reference
strains from established
genotypes (A to H) from the
NCBI GenBank. The blue
triangles indicate an aberrant
genotype. The evolutionary
relationship was inferred using
the ML method based on the
Kimura model. Malaysian
isolates are indicated by HBV
UPM D followed by isolate
number and all belong to
genotype B, with the exception of
the aberrant strains
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Discussion
In this study, HBV DNA was detected in HBsAg-negative
serum using nested PCR, which is in line with previous stud-
ies that demonstrated the same result in peripheral blood
mononuclear cells, serum and liver samples that were negative
for HBsAg, HBV DNA levels were less than 104 copies/mL
[10], which is considerably lower than those that are HBsAg-
positive. Our study revealed a 5.5 % prevalence of the hepa-
titis B core antibody among blood donors and vaccinated un-
dergraduate students, which is similar to that reported in Italy
[11], Egypt [12], Germany, the UK [13] and the USA [14], but
less than that reported in Korea [15] and Greece [16]. This
study revealed a 100 % prevalence of vaccine-escaped hepa-
titis among hepatitis B core antibody-positive blood donors
and vaccinated undergraduates. This is similar to the frequen-
cy reported in China [17]. Additionally, other studies have
reported the identification of vaccine-escaped hepatitis B virus
more frequently in individuals with anti-HBc-positive serolo-
gy than in those with anti-HBc-negative serology, which is in
accordance with our findings. On the other hand, a prevalence
of 33.3 % was reported in northeast China [17], compared to
0.11 % in Taiwan [18]. Occult or vaccine-escaped hepatitis B
infections have significant clinical importance, since they can
become reactivated when the immune system is suppressed
and can be transmitted through the transfusion of blood or
blood products, organ transplant and sexual intercourse. It
may also enhance the progression of liver fibrosis and, subse-
quently, hepatocellular carcinoma.
Our results showed that all isolates belonged to a single
genotype, B, which is in agreement with previous studies that
confirmed genotypes B and C as the most prevalent in Asia
[19]. However, in Malaysia, genotype B was reported to be
dominant over C [20], which is in contrast to the findings in
asymptomatic carriers in China, where genotype Cwas report-
ed as being dominant [5].
Most of the sequences were found to exhibit a close rela-
tionship with reference isolate 14 (JX869999) from Panama,
which belongs to genotype B, serotype adw2 and was isolated
from plasma. Other isolates, including UPMD301 and
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Fig. 4 Molecular phylogenetic
relationship of Malaysian
hepatitis B virus (HBV) isolates
from vaccinated individuals with
reference isolates from the NCBI
GenBank. The evolutionary
relationship was inferred using
the ML method based on the
Jukes–Cantor model. Malaysian
isolates are separated into two
distinct clusters marked in frames
(red and blue)
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UPMD170, were closely related to reference isolates from
Canada, the Philippines and Indonesia. One of the Malaysian
isolates, UPMD179, was found to be distantly related to all
other isolates, but to have a close relationship with isolate
M13008 (KC315324) from Thailand, which belong to geno-
type B, serotype adw, isolated from serum [21]. On the other
hand, sequences from vaccinated Malaysian individuals were
separated into two clusters, the majority of which were found
to have a close evolutionary relationship with reference iso-
lates from China, Taiwan and Japan. However, some se-
quences from vaccinated individuals were distantly related
to other sequences belonging to different clades and sub-
clades as a result of frequent mutations within the S gene.
The hepatitis B viral DNA polymerase enzyme lacks proof-
reading ability, making it highly susceptible to nucleotide
misincorporation during reverse transcription or replication
[22]. Mutations in the S gene are the most concerning from a
clinical point of view, because of the difficulty in establishing
a diagnosis, leading to the progression of undiagnosed cases to
occult chronic infection, liver failure and, subsequently, hepa-
tocellular carcinoma. The development of mutations in the S
gene of HBV interferes with the viral antigen recognition by
antibodies in serological assays, as well as with the response
to recombinant hepatitis B vaccine. Several types of mutations
were implicated, many of which affect amino acids within the
a determinant region of the S gene; however, our results show
that the majority (94.3 %) of mutations occurred outside the
major hydrophilic region. As all of our sequences have muta-
tions outside the a determinant region, it can be concluded
from our findings that mutations outside the a determinant
region may play a significant role in vaccine-escaped hepatitis
B mutant infection as a result of the failure to detect HBsAg in
the sera. Only 6/105 (5.7 %) of the mutations were located
within the a determinant region: T125K, D144G, T125A,
S132C and M133L. Therefore, our findings suggest that mu-
tations within the a determinant region, as well as other re-
gions of the S gene, may play a significant role in the diagnosis
and detection of vaccine-escaped hepatitis B infection, which
is in agreement with the findings from previous studies. How-
ever, we found mutations at positions 133 and 144 in isolates
UPMD170 and UPMD375, respectively, which concurred
with reports from China and Turkey [23] and were described
as ‘immune-selected mutations’ [24]. However, the mutation
at position 133 aa creates an N-linked glycosylation site,
which can effectively rescue the effects of the G145R mutant
virion and, to some extent, other immune-escaped mutants
[25]. Premature stop codons were found in isolates UPMD47,
UPMD95, UPMD348, UPMS45, UPMS139, UPMS186,
UPMS388 and UPMS389, which might affect HBsAg pro-
duction, as described previously [26].
The most prevalent mutation found in this Malaysian iso-
late was the substitution of glutamine at position 16, which is
in contrast to the previous report of G145R being the most
common mutation [27]. None of our isolates contained a mu-
tation at position 145 of the amino acid sequence and, yet,
HBsAg could not be detected using commercial ELISA kits.
Thus, it can be speculated that mutants with defects in the S
gene of the HBV genome at position 16 lead to the loss of
Table 4 Distribution of amino
acid (aa) mutations within
different regions of the surface
protein. The a determinant region







T125K V106F Q16K, G18V, G18R, G18M, L95Stop
D144G S117R T37N, T37I, S61Stop, F19L, F20L, W35R,
W35G, W36C, W36R, G50A, G50D, G50V,
H60P, H60S, R73L, I82L, V168L
T125A C121W T23I, V47G, C48G, C48V, L49I, Q54H
T125I T123N I25N, S55P, S55G, L12Q, L12P, L12R
S132C T148A V14L, V14G, Q16R, V180G, N52S, D99G
M133L S155X P29L, L13F, P11T, Q56T, S58Y, S132T
A157D 165Stop, L15Stop, I28T, I28E, S59R
T125K S59N, S64F, S64G, I68V, C69F, C90F
D144G C90R, C90S, F93V, F93L, L94M, I92H
T125A I92L, Q51Stop, F80L, C85G, C85F, C85L
T125I I86F, I86V, T63S, L88M, T27R, Q30R
S132C D33N, D33S, N40D, P62H, P62Q, R78W
M133L L89R, W74R, P66L, L39I, L39T, K24Q
P151L I57T, S53Y, Q54Stop
L109P
Total: 6 15 90
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HBsAg expression, which is the main target for serological
diagnosis. This might be the result of post-transcriptional ef-
fects of mutations on HBsAg expression, as described previ-
ously [28], resulting in HBV-escaped mutant infection; how-
ever, further functional studies in cell culture are required.
This suggests that mutations outside the MHR can also lead
to the development of escaped mutant strains of hepatitis B
and subsequent serological diagnostic failure, which concur




Fig. 5 Multiple sequence alignment of deduced amino acids of hepatitis
surface antigen major hydrophilic region (MHR) of 55 Malaysian
sequences compared with a reference sequence from the NCBI
GenBank. The antigenic region (a determinant) is boxed (red). The
MHR is from 100 to 160 aa and the a determinant from 124 to 147 aa
Eur J Clin Microbiol Infect Dis (2015) 34:1349–1359 1357
Limitations
Wewere not able to obtain a known G145R escaped mutant to
use as a control, and, thus, we relied on sequencing of the
gene. The ability of the S region to secrete surface antigen
was not determined in vitro, but carriers of this escapedmutant
are being followed up.
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